Allogene Therapeutics
Leonidas Pavlos Kyparissous has a diverse work experience history. Leonidas Pavlos began their career at OTE as a Telecommunications Engineer in 2011 and later worked at Roadshow Events as an Audio and Visual Services professional from 2005 to 2013. In 2014, they served as a Lab Supervisor at USC Viterbi School of Engineering. From 2015 to 2018, they held multiple roles at International Process Solutions Inc., including Calibration Technician and Field Service Lead Engineer. In 2018, they joined AbbVie as a Quality Engineer II. Currently, they are working at Allogene Therapeutics, where they have held various positions including Senior Manager, Lab Asset Management, Associate Director, Lab and Manufacturing Asset Management, and most recently, Director, Lab, Manufacturing, and Quality Asset Management.
Leonidas Pavlos Kyparissous obtained a Bachelor's degree in Mechatronics, Robotics, and Automation Engineering from the Technologiko Ekpaideutiko Idrima, Chalkidas from 2005 to 2012. Leonidas Pavlos subsequently pursued a Master's degree in Bioengineering and Biomedical Engineering from the University of Southern California from 2013 to 2014.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.